HLB's Lypictu enters EU review chasing an FGFR2 market about 40% smaller than America's

The FGFR2 segment is the part of the market the drug can sell into, because lirafugratinib targets only the FGFR2 alterations found in a subset of bile duct cancer patients ^[6]. On the industry estimates, that subset is about a fifth of each region's bile duct market ^[17]. The US and European segments together come to $175 million, and Europe is 37% of that ^[18]. A European approval would add a market about 59% the size of the American one ^[19].

Those are estimates of the whole pool. HLB's revenue will be whatever share of it Lypictu wins. The drug is meant for patients who have developed resistance to existing therapies ^[16], so it reaches them after another treatment has stopped working. HLB now has one market where it can sell ^[4] and one where it has applied ^[3], and the report does not give a timetable for a European decision.

Spending has moved ahead of sales. HLB's R&D fell from 48.8 billion won in 2023 to 41.2 billion won in 2024, then rose to 59.9 billion won last year, according to the Financial Supervisory Service ^[10]. The report attributes the 45% one-year jump ^[20] to a sharp expansion of clinical and R&D investment around the time of the approval ^[11]. The report converts the US FGFR2 segment to 150 billion won ^[1]. On that basis, last year's R&D bill equals about 40% of the segment's entire annual value ^[21].

An unnamed official at a domestic securities firm said the FDA approval shows whether a Korean biotech can link approval directly to global commercialization without relying on technology licensing or milestone payments ^[12]. Selling through its own US subsidiary ^[15], HLB gives up the upfront and milestone cash a licensee would pay. It also pays for its own sales force and supply chain.

Several outcomes are open. Strong US uptake would make a European approval an extension of a sales model that already works. Slow uptake would leave HLB building a second, smaller market before the first has paid for itself. A late European decision would leave the US carrying the drug alone for longer.

In my view the US launch is the whole near-term case, and the European filing is an option on the smaller segment ^[1]. The counter-case is that one set of trial data and one medical team can cover a combined pool of $175 million instead of $110 million ^[18], so Europe costs less to add than its size suggests. I am wrong if early US sales show Lypictu taking a large share of the American segment. In that case Europe's smaller pool is upside on a model that has already worked.